Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341421 | 0.85 | MMP9 (0.52) | LMNAKDM4EALDH1A1LIPEMAPT | |
| SCHEMBL18275289 | 0.81 | MMP9 (0.49) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2665963 | 0.80 | LMNA (0.56) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2665972 | 0.80 | KMT2A (0.57) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL27513611 | 0.80 | CYP1A2 (0.62) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL185256 | 0.79 | DDIT3 (0.49) | ALDH1A1LIPEMAPTGAA | |
| SCHEMBL18275183 | 0.79 | POLB (0.69) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL13033311 | 0.79 | KDM4E (0.38) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL68851 | 0.79 | CYP4Z1 (0.62) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL119585 | 0.78 | LMNA (0.54) | LMNAKDM4EALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| EP-2195304-B1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-01-08 | — | — | EP | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2402327-A1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | Advinus Therapeutics Private Limited (IN) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011080755-A1 | FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080755-A1 | FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2195304-A2 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | Advinus Therapeutics Private Limited (IN) | 2010-06-16 | — | — | EP | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2009047798-A2 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | GCK, GCKR, ALDOA | LMNA 2989/4885KDM4E 3939/4885ALDH1A1 843/4885 |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | LMNA 4332/4885KDM4E 564/4885ALDH1A1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.